Swayam Pakula Ramakant (R.K.)
Analyst
H.C. Wainwright
Equibles does not estimate personal net worth.
About Swayam Pakula Ramakant (R.K.)
Swayam Pakula Ramakant (R.K.) is recorded as Analyst at H.C. Wainwright. Swayam Pakula Ramakant (R.K.) has spoken on 5 earnings calls across 5 companies, most recently for Intensity Therapeutics, Inc. on August 11, 2026. Those appearances were for Intensity Therapeutics, Inc. (INTS), INNATE PHARMA, Absci Corp (ABSI), Eton Pharmaceuticals, Inc. (ETON) and Vericel Corp (VCEL). The companies whose calls Swayam Pakula Ramakant (R.K.) spoke on are classified in the Healthcare sector.
Swayam Pakula Ramakant (R.K.) on recent calls
“And then, Lou, will all the 21 patients that had been enrolled before the pause remain in the primary intent-to-treat analysis? And, you know, did the interruption affect anything, especially the anticipated timing or number of overall survival events that need to happen?”
“You know, regarding the Nectin 4 ADC, you know, you're – it's just Lily's products, which are in phase one, and bicycles, you know, recently deprioritized their product.”
“I apologize that I'm going to disappoint you by not asking your question on 201 or 202. However, I have a couple of other questions. One is you stated that you're de-emphasizing oncology products.”
“Just to talk a little bit about the Kindevia launch. You know, you were stating that there are about 60% of the patients are age 4 and older. That's four and below, I'm sorry, that's four and below, sorry, four and below, yeah, I'm reading wrong from my notes.”
“So in your prepared remarks, Joe, you were talking about there's a potential for the burn franchise to outperform your 10 million per quarter guidance. So what are the pushes and pulls for that to happen?”
Affiliation history
-
H.C. Wainwright
Analyst
Transcript header (unverified)
Current
Company network
INNATE PHARMA
Biotechnology · Healthcare
ABSI
Biotechnology · Healthcare
Drug Manufacturers - Specialty & Generic · Healthcare
VCEL
Biotechnology · Healthcare
Recent activity
-
-
Earnings call
INNATE PHARMA Q1 FY2026 Earnings Call
INNATE PHARMA
-
-
-